These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 8683038)
1. Pretreatment of human peripheral blood lymphocytes with interleukin-2 or dexamethasone does not alter their response to Met-Enkephalin in a NK-cytotoxic assay. Martin-Kleiner I; Gabrilovac J Immunopharmacol Immunotoxicol; 1996 Feb; 18(1):37-57. PubMed ID: 8683038 [TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102 [TBL] [Abstract][Full Text] [Related]
3. Naloxone modulates NK-cell activity of human peripheral blood lymphocytes like an opioid agonist. Martin-Kleiner I; Gabrilovac J Immunopharmacol Immunotoxicol; 1993; 15(2-3):179-97. PubMed ID: 7688780 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. Nair MP; Schwartz SA J Immunol; 1984 Jun; 132(6):2876-82. PubMed ID: 6202765 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human natural killer cell activity by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine is an early but post-binding event. Steele TA; Brahmi Z J Immunol; 1988 Nov; 141(9):3164-9. PubMed ID: 3262683 [TBL] [Abstract][Full Text] [Related]
6. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes. Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261 [TBL] [Abstract][Full Text] [Related]
7. [The effect of sera of breast cancer patients on NK cell activity]. Konjević G; Spuzić I Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436 [TBL] [Abstract][Full Text] [Related]
8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
9. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757 [TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. Cesano A; Visonneau S; Clark SC; Santoli D J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216 [TBL] [Abstract][Full Text] [Related]
12. Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. Shau H; Golub SH J Immunol; 1985 Feb; 134(2):1136-41. PubMed ID: 3871208 [TBL] [Abstract][Full Text] [Related]
13. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. Naume B; Gately M; Espevik T J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169 [TBL] [Abstract][Full Text] [Related]
14. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Owen-Schaub LB; Gutterman JU; Grimm EA Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408 [TBL] [Abstract][Full Text] [Related]
15. Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Gatti G; Masera RG; Pallavicini L; Sartori ML; Staurenghi A; Orlandi F; Angeli A Brain Behav Immun; 1993 Mar; 7(1):16-28. PubMed ID: 8386029 [TBL] [Abstract][Full Text] [Related]
16. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
17. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Gan X; Zhang L; Solomon GF; Bonavida B Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684 [TBL] [Abstract][Full Text] [Related]
19. Effect of human alpha-fetoprotein on native and in vitro-stimulated NK activity. Cardoso E; Valdez G; Comini E; Matera L J Clin Lab Immunol; 1991 Apr; 34(4):183-8. PubMed ID: 1726567 [TBL] [Abstract][Full Text] [Related]
20. Effect of interleukin-2 on the monomeric IgG-induced inhibition of human natural killer cell activity. Gherman M; Herberman RB; Sulica A Nat Immun Cell Growth Regul; 1989; 8(5):255-65. PubMed ID: 2512481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]